Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors

Characterization of human plasma growth inhibitory activity on serum-free mouse embryo cells.

In vitro cellular & developmental biology. Animal·2016

Cell and molecular biology of the spiny dogfish Squalus acanthias and little skate Leucoraja erinacea: insights from in vitro cultured cells.

Journal of fish biology·2012

Transfection of cultured fish cells with exogenous DNA.

Cytotechnology·2012

Culture of cells from two life stages of Schistosoma mansoni.

Cytotechnology·2012

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Lancet (London, England)·2026

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Lancet (London, England)·2026

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

Lancet (London, England)·2026

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Lancet (London, England)·2026

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Lancet (London, England)·2026

Human leukocyte antigen loss as a mechanism of immune escape after allogeneic stem cell transplantation in a patient with mycosis fungoides.

Haematologica·2026

Effects of post-transplant cyclophosphamide on immune reconstitution after haploidentical and HLA-matched transplant.

Blood advances·2026

Multidimensional Analysis of Immune Rejection in a Murine HLA-Mismatched Laryngeal Transplant Model.

The Laryngoscope·2026

Beyond Histocompatibility: Donor Tissue Immune States and Their Role in Heart Transplantation.

International journal of molecular sciences·2026

Takotsubo Syndrome in Solid Organ Transplant Recipients: Current Evidence, Clinical Challenges, and Future Perspectives-A Narrative Review.

Journal of clinical medicine·2026

Postpartum Triple Allograft Injury with Atypical Hemolytic Uremic Syndrome, Recurrent IgA Nephropathy, and Antibody-Mediated Rejection in a Kidney Retransplant Recipient: A Case Report.

Journal of clinical medicine·2026

Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors

Related Experiment Videos

Related Concept Videos

Characterization of human plasma growth inhibitory activity on serum-free mouse embryo cells.

Cell and molecular biology of the spiny dogfish Squalus acanthias and little skate Leucoraja erinacea: insights from in vitro cultured cells.

Transfection of cultured fish cells with exogenous DNA.

Culture of cells from two life stages of Schistosoma mansoni.

The 2026 report of the Lancet Countdown on health and climate change: a decade of escalating health harms and a decisive moment for all.

Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third-generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China.

Sacituzumab tirumotecan versus treatment of physician's choice in previously treated endometrial cancer (TroFuse-005/ENGOT-en23/GOG-3095): a randomised, open-label, phase 3 trial.

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

First-line pembrolizumab versus carboplatin plus paclitaxel in participants with mismatch repair-deficient advanced or recurrent endometrial cancer (KEYNOTE-C93/GOG-3064/ENGOT-en15): interim analysis of a multicentre, open-label, randomised, active-comparator controlled, phase 3 trial.

Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open-label, phase 3 trial in China.

Human leukocyte antigen loss as a mechanism of immune escape after allogeneic stem cell transplantation in a patient with mycosis fungoides.

Effects of post-transplant cyclophosphamide on immune reconstitution after haploidentical and HLA-matched transplant.

Multidimensional Analysis of Immune Rejection in a Murine HLA-Mismatched Laryngeal Transplant Model.

Beyond Histocompatibility: Donor Tissue Immune States and Their Role in Heart Transplantation.

Takotsubo Syndrome in Solid Organ Transplant Recipients: Current Evidence, Clinical Challenges, and Future Perspectives-A Narrative Review.

Postpartum Triple Allograft Injury with Atypical Hemolytic Uremic Syndrome, Recurrent IgA Nephropathy, and Antibody-Mediated Rejection in a Kidney Retransplant Recipient: A Case Report.

Acute graft-versus-host disease in recipients of bone-marrow transplants from identical twin donors

Related Experiment Videos

Related Concept Videos

Related Articles